The Oscotec Clinical Trial called Study of Oral SKI-O-703, SYK Inhibitor, in Patients with Persistent and Chronic Immune Thrombocytopenia (ITP)

Sponsored by Oscotec Inc., this is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel dose study to evaluate the efficacy and safety of SKI-0-703, and SYK inhibitor, in patient’s with persistent and chronic ITP who have failed to respond (or relapsed after trying) other treatments. Patients in this study must have a platelet count less than 30,000μL on two separate occasion as at least 7 days apart. Participants will take part in three treatment groups for twenty weeks.

USA, Greece, Poland, Spain, Republic of Korea.

https://www.clinicaltrials.gov/ct2/show/NCT04056195?cond=Immune+Thrombocytopenia&cntry=US&draw=2

Recruiting

back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo